BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for chronic lumbar disc disease

Biorestorative

Biorestorative

BRTX

0.00
  • BioRestorative outlined a late-stage Phase 2 program for BRTX-100 in chronic lumbar disc disease, using autologous bone marrow-derived MSCs.
  • Phase 2 is fully enrolled with 105 subjects in a 2:1 randomization; dose set at 40,000,000 cells; topline data targeted for spring 2027.
  • BRTX-100 holds FDA Fast Track designation; primary efficacy targets include at least 30% ODI improvement, at least 30% VAS pain reduction.
  • Blinded Phase 2 updates cited sustained responses; 57% of evaluated patients at two years showed over 50% pain reduction and function restoration.
  • Presentation also highlighted a commercial BioCosmeceuticals platform built on secretome-derived products, supported by an ISO-7 cGMP manufacturing facility.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.